Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Biree Andemariam, MD
Healthcare Provider Associate Professor
Department of Medicine
UConn Health
263 Farmington Avenue
Farmington, Connecticut, United States
Dr. Biree Andemariam is a hematologist and founding director of the New England Sickle Cell Institute (NESCI) at the University of Connecticut Health Center. NESCI was established in 2009 and now serves nearly 300 adults living with sickle cell disease. With a staff of twelve individuals, including nurses, social workers, patient navigators, and research assistants, NESCI provides comprehensive care, acute pain management, specialized blood transfusions, and a destination for children in Connecticut who have aged out of pediatric SCD care.
Dr. Andemariam’s research focuses on developing new pathways of care that improve SCD care quality as well as translational research on deciphering the interplay between red blood cell adhesion to the walls of the circulatory system and the development of pain. She holds an undergraduate degree in molecular biology from Princeton University and a medical degree from Tufts. She is also the Chief Medical Officer of the Sickle Cell Disease Association of America, Inc.
Representative Publications:
Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is Revealed by AFM
+myBinderRelated Content
-
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of AtlantaAs one of the leading pediatric cancer, ...
-
The Regional Comprehensive Sickle Cell Center at Robert Wood Johnson Medical SchoolThe Division of Hematology provides spec...
-
Carla JonesAnyone affected by sickle cell disease k...
-
Nadine Matthie, PhD, RNNadine Matthie is an assistant professor...
-
I Have Sickle Cell Disease. What Should I Know About Going Away to College?When it comes to taking care of yourself...
-
Outcomes of an Emergency Department Observation Unit–Based Pathway for the Treatment of Uncomplicated Vaso-Occlusi...Study objective: This was a prospective...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
